New drug may offer longer-lasting bleed control for rare platelet disorder

This lab study tested whether concizumab, a drug that blocks a natural clotting inhibitor, can improve blood clotting in people with Glanzmann thrombasthenia (GT), a rare genetic bleeding disorder. Blood samples from 20 adults with GT and healthy donors were mixed with concizumab and measured for clot formation. The goal is to see if concizumab could replace current treatments that require frequent injections, offering a longer-lasting (about 3 days) and easier-to-use option.